TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03521453

Intervention type: OTHER
Intervention: PEPPER robot
Description: Presence of a Robot (PEPPER Robot), designed and programmed to give informations, using a screen and vocal. All the patients in the second period will have access to,the robot, while waiting for the visit.
Study: NCT02500069

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: infusion of tap water in all regions (duodenum, jejunum and ileum)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein (in duodenum)
Description: infusion of protein in duodenum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein (in jejunum)
Description: infusion of protein in jejunum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein (in ileum)
Description: infusion of protein in ileum
Study: NCT05539235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: different degrees of adjustment of the injection interval
Description: Treatment was an intravitreal injection of 0.5 mg conbercept using modified T\&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: different degrees of adjustment of the injection interval
Description: Treatment was an intravitreal injection of 0.5 mg conbercept using modified T\&E treatment plans. After 3 months of monthly intravitreal injections, the patients were randomly divided into two groups, and the degree of adjustment of the injection interval was divided into 2 weeks and 4 weeks.
Study: NCT00892164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: harmonic scalpel device (FOCUS)
Description: hemostatic device utilized intraoperatively

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrothermal bipolar vessel sealing system (LIGASURE PRECISE)
Description: hemostatic device utilized intraoperatively
Study: NCT01573624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GSK573719
Description: 100/15.6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GSK573719
Description: 100/31.25

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GSK573719
Description: 100/62.5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GSK573719
Description: 100/125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GSK573719
Description: 100/250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF
Description: 100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/VI
Description: 100/25
Study: NCT04433208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPI
Description: Over-the-counter proton pump inhibitor (PPI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPI
Description: Over-the-counter proton pump inhibitor (PPI)
Study: NCT00999986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 50 mg oral per day for 7 days
Study: NCT04249804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate 1000 MG
Description: intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate 1000 MG
Description: intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering
Study: NCT00945022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wetting lips following surgery using anesthesia
Description: The investigator will position the Lipsus device in accordance with the instructions for use
Study: NCT01624428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 1 mg bid varenicline titrated over a 2 week period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg bid placebo titrated over a 2 week period
Study: NCT02237846

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human umbilical cord tissue-derived mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human umbilical cord tissue-derived mesenchymal stem cells
Study: NCT01897675

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage with packing (wick) placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abscess drainage with loop placement
Study: NCT02722928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled Ventilation with 100% oxygen
Description: Patients in group B will be switched from conventional 1:1 oxygen / air ventilation to 100% oxygen controlled ventilation once tumor resection is completed and hemostasis started. They will inhale 100% oxygen until extubation
Study: NCT01281748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous methylprednisolone
Description: methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intravenous normal saline solution
Description: 50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
Study: NCT04099667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2; Low Dose MYOBLOC
Description: Intramuscular injections on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2; High Dose MYOBLOC
Description: Intramuscular injections on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phase 2; Placebo
Description: Intramuscular injections on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 3; MYOBLOC
Description: Intramuscular injections on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phase 3; Placebo
Description: Intramuscular injections on Day 1
Study: NCT05399524

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Neuronavigation and intraoperative 5-ALA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional pre- and intra-operative imaging
Description: Additional DTI scan during routine pre-operative tumour MRI scan, additional use of intraoperative ultrasound in addition to normal to standard of care (Neuronavigation and intraoperative 5-ALA)
Study: NCT02974985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injection of Restylane Lyft and Restylane L
Description: Intervention--Injections of volumizing products to the midface, nasolabial fold, and marionette folds in female patients in two different age groups

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injection of Restylane Lyft and Restylane L
Description: Intervention--Injections of volumizing products to the midface, nasolabial fold, and marionette folds in female patients in two different age groups
Study: NCT02743572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron sucrose-1
Description: iron sucrose-1 group with PN of iron supplementation of 100μg/kg/d

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron sucrose-2
Description: iron sucrose-2 group with PN of iron supplementation of 200μg/kg/d

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron sucrose-3
Description: iron sucrose-3 group with PN of iron supplementation of 300μg/kg/d

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron sucrose-4
Description: iron sucrose-4 group with PN of iron supplementation of 400μg/kg/d
Study: NCT03066765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linguaflex Tongue Retractor
Description: Tongue implant
Study: NCT01185327

Intervention type: BEHAVIORAL
Intervention: Breastfeeding
Description: Breastfeeding
Study: NCT01974193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floseal
Description: application of floseal on intervention arm
Study: NCT03079414

Intervention type: PROCEDURE
Intervention: Invasive Electrophysiology Study
Description: Invasive electrophysiology studies will be performed using four catheters placed in the right ventricular apex, the coronary sinus, the His bundle region, and the high right atrium. Standard induction protocols for supraventricular and ventricular arrhythmias will be utilized in the absence and presence of isoproterenol. Long-short ventricular extra-stimuli will also be delivered to screen for bundle branch reentrant ventricular tachycardia. The study is considered observational as the participating sites perform electrophysiology studies in this patient population as part of standard clinical care.
Study: NCT03873038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1.~Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1.~Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1.~Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1.~Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22.
Study: NCT02770534

Intervention type: PROCEDURE
Intervention: blood test
Description: 10mls extra mls of blood taken during usual phlebotomy procedures

Intervention type: PROCEDURE
Intervention: blood test
Description: 10mls extra mls of blood taken during usual phlebotomy procedures
Study: NCT03873038

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.
Study: NCT02135523

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: involved-field radiation therapy
Description: Participants will receive involved-field radiotherapy (external beam radiotherapy or brachytherapy) over 45Gy for residual or locoregionally recurrent epithelial ovarian cancer after definitive treatment. Patients will be treated with 1.8-2.0Gy fraction, five times per week. It starts 2 weeks later of chemotherapy.
Study: NCT03398564

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector Spinae Plan Block
Description: The trocar site incision was done 15 minutes after the block in the three groups. The skin was disinfected with chlorhexidine solution, and the high-frequency transducer was isolated with a sterile disposable plastic cover and gel. The patient was placed in lateral position. A high-frequency linear ultrasound probe was placed longitudinally lateral to the T8 spinous process by 3 cm. After identification of the 3 muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced in a cephalo-caudal orientation. The needle tip was positioned fascial plane between rhomboid major and erector spinae muscles. Hydrodissection by 1-2 ml of normal saline to visualize the plan, then deposition of local anesthetic was done. A total of 20 mL of 0.25% bupivacaine was injected here. The same procedure was repeated on the other side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plan Block
Description: The trocar site incision was done 15 minutes after the block in the three groups. The skin was disinfected with chlorhexidine solution, and the high-frequency transducer was isolated with a sterile disposable plastic cover and gel. The patient was placed in lateral position. A high-frequency linear ultrasound probe was placed longitudinally lateral to the T8 spinous process by 3 cm. After identification of the 3 muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced in a cephalo-caudal orientation. The needle tip was positioned fascial plane between rhomboid major and erector spinae muscles. Hydrodissection by 1-2 ml of normal saline to visualize the plan, then deposition of local anesthetic was done. A total of 20 mL of 0.25% bupivacaine was injected here. The same procedure was repeated on the other side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oblique subcostal TAP
Description: ultrasound-guided bilateral oblique subcostal TAP block with bupivacaine 0.25% (20ml on each side)
Study: NCT03883321

Intervention type: OTHER
Intervention: Cognitive behavioral stress management
Description: Management of patients in 10 group sessions with cognitive and behavioral therapies associated with relaxation in order to learn how to manage stress
Study: NCT01389050

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy
Description: Radiotherapy for the treatment of retroperitoneal sarcoma. IMRT will be 50.4 Gy given in 28 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Daily Cone Beam CT
Description: Images and information from the daily CT will be used for the repositioning of the patient prior to their treatments as per standard procedures.
Study: NCT01348048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialised palliative care (SPC)
Description: The interventions given by the SPC centres follow the the WHO and the EAPC guidelines for palliative care. It is not possible in advance to describe the interventions more specifically as these will be adjusted to each particular patient. As part of the study the medical records of all patients in the intervention group will be reviewed with the purpose of describing the interventions given for the different symptoms and problems.
Study: NCT03687320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-Cure Pro
Description: The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
Study: NCT00786799

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 Fatty Acids
Description: Omega-3 Fatty Acids in orange pudding form~1 packet two times per day
Study: NCT03629015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stemchymal®
Description: ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
Study: NCT02772744

Intervention type: DRUG
Intervention: Daclatasvir 60 MG Oral Tablet [Daklinza]
Description: Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein

Intervention type: DRUG
Intervention: Daclatasvir 60 MG Oral Tablet [Daklinza]
Description: Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein

Intervention type: DRUG
Intervention: Daclatasvir 60 MG Oral Tablet [Daklinza]
Description: Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein

Intervention type: DRUG
Intervention: Sofosbuvir 400 MG Oral Tablet [Sovaldi]
Description: Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor

Intervention type: DRUG
Intervention: Sofosbuvir 400 MG Oral Tablet [Sovaldi]
Description: Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor

Intervention type: DRUG
Intervention: Sofosbuvir 400 MG Oral Tablet [Sovaldi]
Description: Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor

Intervention type: DRUG
Intervention: Ribavirin Oral Product
Description: Ribavirin (twice-daily) dosed according to body weight (\<75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)

Intervention type: DRUG
Intervention: Ribavirin Oral Product
Description: Ribavirin (twice-daily) dosed according to body weight (\<75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)
Study: NCT01748097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate 4.2%
Study: NCT04873544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocols for TKA
Description: ERAS protocols for TKA
Study: NCT02240836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention. Exercise
Description: Physical activity. Attendance in exercise groups 60 min. twice a week and exercise at home 120 min per week. Intervention for 12 months.
Study: NCT02987465

Intervention type: DRUG
Intervention: Darbepoetin Alfa
Description: Darbepoetin is not a study drug and is prescribed as part of routine treatment of anaemia in CKD1. Darbepoetin is licensed for use for the treatment of anaemia in the context of CKD. It will be provided as part of the standard clinical care of the renal patients in this study. Healthy Volunteers will not be treated with Darbepoetin.

Intervention type: DRUG
Intervention: Acetylcholine
Description: Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation

Intervention type: DRUG
Intervention: Acetylcholine
Description: Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation

Intervention type: DRUG
Intervention: Noradrenaline
Description: Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist

Intervention type: DRUG
Intervention: Noradrenaline
Description: Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist

Intervention type: DRUG
Intervention: BQ 123
Description: BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.

Intervention type: DRUG
Intervention: BQ 123
Description: BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.
Study: NCT02416596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: Office hysteroscopy will be performed during the Luteal phase of the proceeding menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscope
Description: The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 4-mm diameter diagnostic sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg
Study: NCT02729441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramipril
Description: Comparison of two renin angiotensin aldosterone inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perindopril
Description: Comparison of two renin angiotensin aldosterone inhibitors
Study: NCT00592124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Description: 1 gm/100 ml of 1% gel vaginally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Description: 1 gm/100 ml of 1% gel vaginally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Description: 1 gm/100 ml of 1% gel vaginally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Description: 1 gm/100 ml of 1% gel vaginally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Description: 1 gm/100 ml of 1% gel vaginally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Description: 1 gm/100 ml of 1% gel vaginally daily
Study: NCT00703924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279,396
Description: A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion
Study: NCT00323648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis
Description: Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
Study: NCT00478842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Deep brain stimulation
Study: NCT01916382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: drug
Study: NCT00842556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 20 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Tablets, Oral, 4 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Tablets, Oral, 4 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Tablets, Oral, 100 mg, Single Dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Tablets, Oral, 100 mg, Single Dose
Study: NCT03853135

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of serum endocan
Description: measurement of serum levels of endocan

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of serum endocan
Description: measurement of serum levels of endocan